Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Follow-Up Study of Phase III Study of SyB L-0501 in Combination With Rituximab to Treat Recurrent/Relapsed Diffuse Large B-Cell Lymphoma (Protocol Number: 2017002)

NCT04354402 is registered in ClinicalTrials.gov with SymBio Pharmaceuticals as lead sponsor.

NCT NCT04354402
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04354402 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Follow-Up Study of Phase III Study of SyB L-0501 in Combination With Rituximab to Treat Recurrent/Relapsed Diffuse Large B-Cell Lymphoma (Protocol Number: 2017002)
Lead sponsor
SymBio Pharmaceuticals
Phase
Observational
Overall status
Completed
Start date
March 26, 2020
Completion date
November 11, 2020
Enrollment
25 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b cell lymphoma